Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acid esters
Reexamination Certificate
2008-07-29
2008-07-29
Eyler, Yvonne (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acid esters
C424S184100, C530S403000
Reexamination Certificate
active
07405320
ABSTRACT:
Disclosed are compounds that include two or more haptens conjugated by a spacer or a carrier. The haptens may include diethylenetriaminepentaacetate (DTPA), histimine-succinyl-glutamine (HSG), or combinations of DTPA and HSG. The compound also includes an effector molecule which may be conjugated to one or more of the haptens, the spacer/carrier, or both. The effector molecule may be conjugated by a number of linkages including an ester linkage, an imino linkage, an amino linkage, a sulfide linkage, a thiosemicarbazone linkage, a semicarbazone linkage, an oxime linkage, an ether linkage, or combinations of these linkages. Also disclosed are methods of synthesizing the compounds and/or precursors of the compounds.
REFERENCES:
patent: 2668165 (1954-02-01), Carpenter
patent: 4468457 (1984-08-01), Goldenberg et al.
patent: 4735210 (1988-04-01), Goldenberg
patent: 4737453 (1988-04-01), Primus
patent: 4792521 (1988-12-01), Shochat
patent: 4818709 (1989-04-01), Primus
patent: 4863713 (1989-09-01), Goodwin et al.
patent: 4971792 (1990-11-01), Steplewski et al.
patent: 5078998 (1992-01-01), Bevan et al.
patent: 5101827 (1992-04-01), Goldenberg
patent: 5128119 (1992-07-01), Griffiths
patent: 5183756 (1993-02-01), Schlom
patent: 5225541 (1993-07-01), Hackett et al.
patent: 5274076 (1993-12-01), Barbet et al.
patent: 5328679 (1994-07-01), Hansen et al.
patent: 5336278 (1994-08-01), Adams et al.
patent: 5469854 (1995-11-01), Unger et al.
patent: 5502037 (1996-03-01), Kondratyer
patent: 5503987 (1996-04-01), Wagner
patent: 5514810 (1996-05-01), Platzek et al.
patent: 5534254 (1996-07-01), Huston
patent: 5534756 (1996-07-01), Huston et al.
patent: 5541297 (1996-07-01), Hansen et al.
patent: 5591828 (1997-01-01), Bosslet et al.
patent: 5676923 (1997-10-01), Platzek et al.
patent: 5676926 (1997-10-01), Platzek et al.
patent: 5683694 (1997-11-01), Bagshawe et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5697902 (1997-12-01), Goldenberg
patent: 5716595 (1998-02-01), Goldenberg
patent: 5736120 (1998-04-01), Srinivasan
patent: 5746996 (1998-05-01), Govindan et al.
patent: 5753206 (1998-05-01), McBride et al.
patent: 5772981 (1998-06-01), Govindan et al.
patent: 5776093 (1998-07-01), Goldenberg
patent: 5776094 (1998-07-01), Goldenberg
patent: 5776095 (1998-07-01), Goldenberg
patent: 5780670 (1998-07-01), Yamamoto et al.
patent: 5820849 (1998-10-01), Schmitt-Willich et al.
patent: 5837242 (1998-11-01), Holliger et al.
patent: 5837243 (1998-11-01), Deo et al.
patent: 5851527 (1998-12-01), Hansen
patent: 5874061 (1999-02-01), Schmitt-Willich et al.
patent: 5959083 (1999-09-01), Bosslet et al.
patent: 6004529 (1999-12-01), Yu et al.
patent: 6010680 (2000-01-01), Govindan et al.
patent: 6039773 (2000-03-01), Cherpeck
patent: 6063361 (2000-05-01), Schmitt-Willich et al.
patent: 6077499 (2000-06-01), Griffiths
patent: 6080785 (2000-06-01), Platzek et al.
patent: 6096289 (2000-08-01), Goldenberg
patent: 6121424 (2000-09-01), Whitlow et al.
patent: 6126916 (2000-10-01), McBride
patent: 6187284 (2001-02-01), Griffiths
patent: 6248306 (2001-06-01), Schmitt-Willich et al.
patent: 6280706 (2001-08-01), Yu et al.
patent: 6962702 (2005-11-01), Hansen et al.
patent: 7074405 (2006-07-01), Hansen
patent: 7199268 (2007-04-01), Platzek et al.
patent: 2002/0006379 (2002-01-01), Hansen et al.
patent: 0263046 (1988-04-01), None
patent: 0511011 (1992-10-01), None
patent: 0517024 (1992-12-01), None
patent: 0623675 (1994-09-01), None
patent: 0419387 (1996-11-01), None
patent: 921782 (1992-12-01), None
patent: 03173900 (1991-07-01), None
patent: WO 9604313 (1996-02-01), None
patent: WO 9725305 (1997-07-01), None
patent: WO 97/41898 (1997-11-01), None
patent: WO 9808875 (1998-03-01), None
patent: WO 99/66951 (1999-12-01), None
patent: WO 00/34317 (2000-06-01), None
Boisferon, Hillairet de et al., “Enhanced Targeting Specificity to Tumor Cells by Simultaneous Recognition of Two Antigens” Bioconjugate Chem. 2000 11, 252-460.
Pluckthun et al., “New protein engineering approaches to Multivalent and bispecific antibody fragments,” Immunotechnology 3 (1997) 83-105.
Pack et al., “Tetravalent Miniantibodies with High Avidity Assembling inEscherichia coli,” J. Mol. Biol. (1995) 246, 28-34.
Sharkey et al., “A Universal Pretargeting System for Cancer Detection and Therapy Using Bispecific Antibody,” Cancer Research 63, 354-363 (Jan. 15, 2003).
Karacay et al., “Studies on a Humanized anti-CEA x murine anti-(In- DTPA) bispecific antibody construct for radioimmunotherapy of CEA-positive tumors,” Proceedings of the American Association for Cancer Research Annual Meeting, vol. 40, p. 644 (Mar. 1999).
Karacay et al., “Pretargeting studies with a humanized anti-CEA X Murine anti-(In- DTPA) bispecific antibody construct and Tc-99m/Re-188 labeled peptide,” Journal of Nuclear Medicine, Vo. 40, No. 5 Suppl., p. 225 (May 1999).
Gautherot et al., “Delivery of Therapeutic doses of Radioiodine using Bispecific antibody-targeted bivalent Hapatens,” Journal of Nuclear Medicine, vol. 39 (11), pp. 1937-1943 (Nov. 1998).
Bodere et al. “Phase I/II trial of two-step radioimmunotherapy in medullary thyroid cancer (MTC) using bispecific anti-CEA/anti-DTPA-in antibody and iodine-131-labeled bivalent hapten,” Journal of Nuclear Medicine, vol. 39, No. 5 Suppl., p. 246 (May 1998).
Bardies et al. “Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer,” Journal of Nuclear Medicine, vol. 37, pp. 1853-1859 (Nov. 1996).
Kraeber-Bodere et al., “Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary tthyroid cancer xenograft,” Journal of Nuclear Medicine, vol. 40 (1), pp. 198-224 (Jan. 1999).
Hosono et al., “Biodistriution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.” Journal of Nuclear Medicine, vol. 39 (9), pp. 1608-1613 (Sep. 1998).
Kranenborg et al., “Development and characterization of anti-renal cell carcinoma x antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma,” Cancer Research, Vo. 55 (23 Wuppl.), pp. 5864S-5867S (Dec. 1, 1995).
Kranenborg et al., “Two-Step radio-immunotargeting of renal-cell carcinoma xenografts in nude mide with anti-renal-cell-carcinoma X anti-DTPA bispecific monoclonal antibodies,” International Journal of Cancer, vol. 75 (1), pp. 74-80 (Jan. 5, 1998).
Gautherot et al., “Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten,” Cancer, vol. 80, No. Supp. 12, pp. 2618-2623 (Dec. 15, 1997).
Bosslet et al., “Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy,” British Journal of Cancer, Vo. 63/5, pp. 681-686 (1991).
Manetti et al. “Intracellular uptake and catabolism of anti-IgM antibodies and bi-specific antibody-targeted hapten by B-lymphoma cells,” Int. J. Cancer, vol. 63(2), pp. 250-256 (1995).
Barbet et al., “Radioimmunotherapy of LS174T colon arcinoma in nude mice using an iodine-131-labeled bivalent hapten combined with an anti-CEAX anti-indium-DTPA bispecific antibody,” Tumor Biology, vol. 18, No. Suppl. 2, p. 31 (Sep. 1997).
McGuinness et al, “Phage diabody repertoires for selection of large number of bispecific antibody fragments,” Nature Biotechnology, 14:1149-1154 (1996).
Alt, et al., “Novel tetravalent and bispecific IgG-like antibody molecules combining single chain diabodies with the immunoglobulin gamma-1 or CH3 region,” FEBS LETT, 454: 90-94 (1999).
Olafsen et al., “IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic Cells,” Immunotechnology, 4(2):141-153 (1998).
Kipriyanov et al., “Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics,” J. Mol. Bi
Goldenberg David M.
Hansen Hans J.
McBride William J.
Noren Carl
Eyler Yvonne
Immunomedics Inc.
Lao MLouisa
Nakashima Richard A.
LandOfFree
Therapeutic and diagnostic conjugates for use with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic and diagnostic conjugates for use with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic and diagnostic conjugates for use with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2774051